Seed · AI & Machine Learning · Warsaw, Poland · Founded 2023 · 20–25 employees
Ingenix.ai is developing a groundbreaking multimodal AI foundation model designed to simulate clinical trials using digital twins, addressing the pharmaceutical industry's massive $50 billion annual investment in clinical trials where 90% of pilot drugs fail to gain regulatory approval. The Warsaw-based company secured €9 million in seed funding in April 2025 from leading investors including Inovo.vc, OTB Ventures, and IFC. Founded by the successful team behind Applica (acquired by Snowflake in 2022), Ingenix's platform integrates genomic, transcriptomic, proteomic, and phenotypic data to predict clinical endpoints and adverse events with unprecedented granularity and speed. The company operates across molecular to population levels, offering pharmaceutical companies a true co-pilot experience for clinical development decision-making.